Cargando…
A randomised, multi‐centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol
Patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) show varying degrees of response to intravenous immunoglobulin (IVIg) therapy. This randomised phase III study in patients with CIDP (ProCID trial) will compare the efficacy and safety of 3 different doses (0.5, 1.0, and...
Autores principales: | Cornblath, David R., Hartung, Hans‐Peter, Katzberg, Hans D., Merkies, Ingemar S. J., van Doorn, Pieter A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033152/ https://www.ncbi.nlm.nih.gov/pubmed/29603842 http://dx.doi.org/10.1111/jns.12267 |
Ejemplares similares
-
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023) -
Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
por: Adrichem, Max E., et al.
Publicado: (2022) -
Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy
por: Cornblath, David R, et al.
Publicado: (2022) -
Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy
por: Kuitwaard, K., et al.
Publicado: (2020) -
Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy
por: Kuitwaard, Krista, et al.
Publicado: (2021)